Conclusion: National incidence and risk factor assessments may become a basis for the evaluation of prevention trials - prospects from the Third Nordic MS Symposium. Andersen O Acta Neurol Scand Suppl. 2015; 132(199):71-5. PMID: 26046562. Abstract CommentRecommendBookmarkWatch